CRYPTOCOCCOSIS: A REVIEW OF THE BRAZILIAN EXPERIENCE FOR THE DISEASE

Mara C.S.M. PAPPALARDO(1) & Márcia S.C. MELHEM(2)

SUMMARY

Cryptococcosis is a systemic mycosis caused by Cryptococcus neoformans. The disease occurs in patients with cellular immunodeficiency. The incidence of cryptococcosis arises with AIDS, and mycosis is one of the opportunistic infections that defines AIDS. After the HAART era the occurrence of cryptococcosis decreased all over the world, but it still continues to be a prevalent disease in Brazil. Thus, we consider this paper to be very important as a result of our reviewing of Brazilian literature regarding some relevant aspects of that disease.

KEYWORDS: Cryptococcus neoformans; Cryptococcosis; AIDS; HAART, Brazilian literature.

INTRODUCTION

Since the discovery of Cryptococcus by Sanfelice, 108 years has passed by, and we know much about this capsulated yeast, but there are many areas to be researched that evolve the interaction of the agent with human host. Some aspects of this binomial are fascinating, but not exactly clear. Some of these aspects of the history of disease, extremely modified by acquired immunodeficiency syndrome (AIDS) and more recently by highly active antiretroviral treatment (HAART). Other aspects are related to the biology of the etiologic agent. The knowledge gained by the studies of molecular biology and of antifungal sensitivity as well biochemical studies about Cryptococcus neoformans virulence have contributed in elucidating several points about that yeast. Studies had became more intensive since the 80’s due to the epidemic AIDS and cryptococcosis has became an important opportunistic infection due to both by increasing the morbidity rates and mortality rates.

Brazilian literature about cryptococcosis contributes significantly due to the elucidation of related facts regarding the agent and the disease. The aim of this study is to review the Brazilian literature, including many unpublished theses that have new findings of great importance and deserve being highlighted in reviews about cryptococcosis.

In Brazil, the honorable professor Dr. Carlos da Silva Lacaz and his master, Dr. Floriano de Almeida, first reported cryptococcosis, here describing the two first reports in 1941 and 1944 respectively, according to REIS-FILHO et al.73.

Ecological and Epidemiological Aspects: Cryptococcosis is a worldwide disease and its occurrence prior to the AIDS epidemic was sporadic and generally associated to low cellular immunity. Currently, cryptococcosis occurs in the general population in a relatively low incidence taking in account the wide distribution of C. neoformans in the environment that makes it possible to foresee a high probability of spore inhalation. Occurrence of subclinical, asymptomatic forms of the disease is unknown and studies, such as cellular immunity surveys using intradermic tests with the yeast antigen in patients without clinical disease are rare, and therefore the extent of the subclinical form has not been properly evaluated.

C. neoformans’ habitat in the environment is on the ground, in decomposed vegetables, bird and bat feces which are found both in urban and rural areas of Brazil3,5,7,27,30,35,38,39,60,67,75,89,90. Studies of LAZERA et al.43,44,45,46 gave new dimensions to the ecology of the cryptococcosis agent in Brazil demonstrating that yeast is associated not only to Eucalyptus sp gender, but also to other species of trees. The most appropriate methodology for C. neoformans isolation from environment samples was well evaluated by MONTENEGRO & PAULA55 and BARONI5 who successfully isolated two species of the yeast in São Paulo and Rio de Janeiro, Brazil.

Infectious particles spread by air represent the most important source of pulmonary contamination after inhalation, and there is no consensus about its origin: whether or not it is sexual (basidiospores) or asexual (conidia)39. Molecular studies with Brazilian samples showed that the majority of infections are caused by heterothallic strains classified as α-phenotypes (mating-type MATα) that are also prevalent in environmental samples of C. neoformans6.

C. neoformans has five serotypes: A, B, C, D and AD of two varieties called neoformans (A, D and AD) and gattii (B and C). FRANZOT et al.38 proposed the reclassification of A-serotype into a new species: grubii. Several epidemiological inquiries show the heterogeneous distribution of these subtypes of cryptococcosis agents in several countries, verifying,

(1) Emílio Ribas Infectious Diseases Institute, São Paulo, SP, Brazil
(2) Adolfo Lutz Institute, Av. Dr. Arnaldo 355, 01246-902 São Paulo, SP, Brazil
Correspondence to: melhemmr@uol.com.br
consequently, the hypothesis of a correlation between etiologic agent variety and geographic regions according to MELO et al. In Brazil, the pioneer study of LACAZ & RODRIGUES showed that the majority (64%) of 25 biological samples belonged to the *C. neoformans* variety with the A-serotype prevailing followed by B and D. Predominance of this serotype into our clinical setting was therefore, confirmed by other authors both with biological and environmental samples. The possibility of transformation between A and AD-serotypes was reported by BARRETO DE OLIVEIRA and REZENDE. The *gattii* species are endemic in the northeast of Brazil, which is responsible for 71% of cases.

Molecular studies about etiologic agents contribute to the comprehension of the Brazilian cryptococcosis epidemiology. An Iberian American study done with strains from nine countries including Brazil showed low genetic variability in 340 strains of *C. neoformans* being 56 clinical and 9 environmental samples. The methodology used was PCR (Polymerase Chain Reaction) associated to RFLP (Restriction Fragment Length Polymorphism) and it revealed only three molecular types of species of Brazilian strains among the eight types of species identified in the study. FRANZOT et al. suggested a clonal origin of strains acquired in Brazilian cases explain the low genetic diversity observed among the 51 samples collected from the cities of Belo Horizonte and Rio de Janeiro by way of PFGE (Pulsed Field Gel Electrophoresis) and RFLP studies, and they have pointed to important differences from North American strains. ALFP (Amplified Fragment Length Polymorphism) methodology applied by BOEKHOUT et al. has confirmed hybridism of *C. neoformans*. VIVALDINI has verified by RAPD (Randomly Amplified Polymorphic DNA) analysis great homogeneity among 89 clinical samples from the São Jose do Rio Preto region, in accordance with a strong similarity of genotypes previously described by ALMEIDA. IGREJA has verified very similar profiles evaluating 60 strains in Rio de Janeiro city. HORTA et al. have applied RAPD technique in 17 clinical samples and 10 environmental samples from Rio Grande do Sul state, and they have verified great differences in molecular profiles. REZENDE, using the same methodology but with other primers also verified genetic heterogeneity without dominance of any molecular type species among clinical samples collected in the cities of Araraquara and Ribeirão Preto, suggesting the absence of a correlation among sources of infection. DNA profile studies made it possible for REZENDE and IGREJA to demonstrate the maintenance of the same agent through all the disease’s course even with antifungal therapy in some cases. In one patient, IGREJA found mixed infection with the two species, *gattii* and *neoformans*.

Generally, *C. neoformans* var. *gattii* infects immunocompetent individuals, such as primary or secondary diseases, in contrast to var. *neoformans*, which has a strong association between the variety and the immune host status. In Brazil, as occurs in other countries, cryptococcosis rates by *gattii* species in patients with AIDS are lower than the population, with other underlying diseases, or even without immunodepression, a data consistent with the worldwide literature. PAULA et al. in a study of the cryptococcosis agent, in 40 cases not associated to infection by HIV, demonstrated the proportion of *gattii* of about 33% while in AIDS patients this rate is below 1%. CORREA et al. have observed alterations, through tomographical images, in 11 immunocompetent children with infection of the central nervous system (CNS) by *gattii* variety. In a study carried out in Rio de Janeiro City, patients with AIDS exposed to spores of *C. neoformans* species in a home environment have presented a risk to cryptococcosis two times more than non-exposed AIDS patients.

NISHIKAWA et al. published the most complete study to the present, in which they proposed that the prevalence of *neoformans* species is not homogeneous all over Brazil considering 467 environmental and biological samples. The authors verified the prevalence of B-serotype as the etiologic agent of non-AIDS patients in the northeast of Brazil. Moreover, interesting data reveal the occurrence of C-serotype in negative HIV patients and high rates of AD-serotypes (1.3%) in relation to D-serotypes (0.4%) in the total samples.

**Clinical and laboratorial aspects:** The influence of agent variety in disease prognosis was well studied by SEVERO that concluded a positive correlation between disease caused by *neoformans* species and death. The predisposed disease was AIDS (48%) or other diseases associated to cellular deficiency (33%) in cases with *neoformans* species. This and other aspects of agent and cryptococcosis diseases can be appreciated in the excellent review published by the author.

The yeast has a strong tropism to CNS but it can occur in localized forms or the disseminated disease associated, or not to AIDS. Systemic forms of the disease are diverse and ZANINI observed ulcer as the first sign. Virulence of the agent invading different organs and its participation in death can be verified in Brazilian studies using histopathology analysis. Meningoencephalitis is the most common form of cryptococcosis infection. About 70% to 90% of patients with AIDS and CNS cryptococcosis have signs and symptoms of sub acute meningitis or meningoencephalitis as follows: headache, fever, lethargy, coma, personality disorder and loss of memory which occurs 2-4 weeks previous to diagnosis. PAPPALARDO showed that in 35 patients the following most common signs and symptoms of cryptococcosis were apparent at the time of diagnosis: cephalgia (97.1%), nausea and/or vomiting (51.4%), fever (34.3%), visual disturbance (20%), altered mental status (11.4%), seizure (8.6%) and menigale signs (5.7%). The same findings had been described but in different proportions by other authors. Cephalgia is the second cause of pain in AIDS patients, and CNS cryptococcosis is responsible for 40% of this symptom.

The disease is more frequent in adults, but despite being rare it can affect children. CORREA et al. considered that in Brazil there is an increase of cryptococcosis rates in the childhood population considering the incidence of 24.4% observed in the group of patients studied. DARZÉ et al. reported a similar incidence of about 30% of 104 cases occurring in the population of less than 15 years old. Cryptococcosis can be associated to other mycoses especially oral candidiasis, dermatophytosis, pityriasis versicolor and also to systemic mycoses, such as paracoccidiomycosis or histoplasmosis according to three cases of AIDS reported by CAIUBY. Laboratory diagnosis of CNS cryptococcosis can be done by cerebral spinal fluid (CFS) examinations or by histopathological assay or even by the polysaccharide capsular antigen test. Several Brazilian authors have related chemocytologic aspects of CFS on cryptococcosis associated or not to AIDS, but a specific pattern of the disease does not exist. The capsule, a morphologic aspect that distinguishes the genre *Cryptococcus* is considered an important factor of yeast virulence; however, there are cases described of the disease caused by
a non-capsulated agent or by low capsule production. Other virulence factors such as phenol oxidase production were studied in clinical strains by REZENDE. PAULA et al. proposed a sensitive and economic procedure to evaluate the production capacity of that enzyme. Phospholipases and proteinases are virulence related enzymes, and SILVA found production rates of 84% and 20% respectively in isolated samples from pigeon excrement. In two other papers, REZENDE using samples from pigeon excrement and VIDOTTO et al. using clinical strains, verified high production of phospholipase in Brazilian strains suggesting that there is strong virulence.

As highlighted in the Brazilian literature, the best option for disease diagnosis in terms of high sensitivity and quick results is the detection of polysaccharide antigen by latex particle agglutination, in body fluids such as: CSF, serum and urine. The disadvantage of this is that it is an imported product and has a high cost. The most economical and practical method having greater specificity and almost 100% sensitivity for cryptococcosis diagnosis is the detection of CSF antigen titer >1024, CFS cell count <20/mm3 and age <35 years. Cryptococcosis can be the first opportunistic infection in AIDS, ranging from 23% to 48.6% according to each study done. The AIDS Bulletin entitled “Boletim AIDS - Cor e Raça” which was published by the Reference and Training Center of Sexually Transmitted Diseases and AIDS (Centro de Referência e Treinamento em DST/AIDS) of the São Paulo State Health Secretary showed that cryptococcosis rate associated to AIDS has been on the average about 3.7% in the last 14 years (www.cvs.gov.sp.br). Data from the Epidemiology Division at the Instituto de Infectologia Emílio Ribas a specialized hospital in Infectious Diseases in São Paulo, Brazil, show that CNS cryptococcosis in AIDS patients both in inpatients and outpatients have generally decreased in the last few years: 7.7% in 1995; 7.4% in 1996; 8.2% in 1997; 6.8% in 1998; 5.8% in 1999. 4.6% in 2000, 3.1% in 2001, remaining unchanged up to April, 2002. At this hospital, the induction phase of cryptococcosis treatment associated to AIDS follows a guideline of a single therapy with AB, usually with a maximum daily dose of 50 mg since, unfortunately the 5-FC drug was unavailable on the Brazilian market for a while. Mortality ascribed to cryptococcosis in 35 AIDS patients at Emílio Ribas Infectious Disease Institute was 79%. General mortality in cryptococcosis patients, with or without underlying disease, is around 45% - 65%, according to Brazilian studies. A study of 17 cases of CNS cryptococcosis showed that clinical aspects, follow-ups and necroscopy findings were influenced by the presence and the kind of immunodeficiency, that is, a worst prognosis being seen in patients with pre-existing primary disease, such as, diabetes or neoplasia, in comparison to immunodepressed cases under renal transplant therapy or immunocompetent patients.

The most important predictive factor of early death is the patient mental status at the time of diagnosis, but other factors are also applicable: CSF antigen titer >1024, CFS cell count <20/mm3 and age <35 years old. Extraneural cryptococcosis, hypernatremia and high counts of fungal cells are also parameters of poor prognosis. Despite of being important factors for prognosis, intracranial hypertension (ICH) and extraneural cryptococcosis were undiagnosed according to a Brazilian retrospective study. Cryptococcosis in AIDS patients was observed in 6.6% of patients with clinical suspicion or previous history of CNS cryptococcosis. Major rates were verified by CORTES on analysis of 70 blood cultures of AIDS patients.

Besides factors that definitely contribute to therapeutic failure, there are hypotheses for the existence of resistant phenotypes to therapy. Resistant phenotypes are identified in populations of several etiologic agents by means of sensitivity tests that can be done by several methods: dilution in liquid medium, dilution and diffusion on agar medium. Comparisons of test results obtained with agar and in liquid medium, dilution and diffusion on agar medium. Comparisons of test results obtained with agar and in liquid medium were done worldwide as well as in Brazil, confirming the test validity. The minimum inhibitory concentration (MIC) of the drug against the etiologic agent is the most-used parameter for detecting resistant strains. Since the 80’s, North American and European groups were implicated in developing a reference method, the most important being respectively, the NCCLS (National Committee for Clinical Laboratory Standards) and the EUCAST (European Committee on Antimicrobial Susceptibility Testing) subcommittees. The current method accepted as reference for the “in vitro” antifungal susceptibility testing is the M27-A2 document from NCCLS. The proposed EUCAST methodology has its guidelines based on NCCLS. However, the M27-A2
document has limitations in non-fermentative yeasts studies of glucose, such as Cryptococcus sp, and therefore there are studies done by Brazilian authors seeking adequate alternative test conditions for work with this genus against natural or synthetic drugs.

In several studies, the majority of C. neoformans human samples are “in-vitro” sensitive to FZ and itraconazole (IZ); on the other hand, up to 50% of the strains are resistant to 5-FC. However, VIVALDINI found clinical strains with less sensitivity to IZ, a fact which was previously reported by ALMEIDA. In another study REZENDE reported around 18% of samples being less sensitive to FZ in accordance with data from PAPPALARDO who found a resistance of 12% in 168 samples collected from 35 patients.

In C. neoformans environmental samples, about 25% presented low sensitivity to FZ while AB and IZ were the most effective antifungals. The difference of the “in-vitro” response to 5-FC between the two agent varieties was noted by MONTENEGRO & PAULA. The E-test method was used by SILVA for analysis of 62 isolated strains of pigeon feces, which were highly sensitive to AB, IZ and ketoconazole (KZ) and resistant to FZ for the most part. ALVES & CURY observed less sensitivity to FZ in clinical samples than in environmental samples and to AB, IZ and KZ, the authors verifying high sensitivity of strains independent of their origin.

Generally, C. neoformans strains, like the majority of yeasts, are “in-vitro” sensitive to AB. However, there are still serious limitations concerning the credibility of results of testing this drug even when using recommended methods. Because of this and other problems, the test results cannot be used in routine medical practice. It is important to highlight that there is no reference method for the carrying out of susceptibility tests for the cryptococcosis agent and also there is a scarcity of worldwide studies in the literature that correlate clinical prognosis to yeast-sensitivity profile. Therefore, there is inconsistency in the correlation of therapy failure with the presence of “in-vitro” resistant C. neoformans strains.

CONCLUSIONS

Existing data at this precise moment suggests that the main cause for therapy failure in CNS cryptococcosis associated with AIDS is due to the low immunity of the host. Moreover, little is known about the antifungal pharmacokinetics in the CNS of the host in the presence of ICH, or of the role of antifungal cell exo-enzymes, or the virulence of the strain, or even of the genetic or physiologic mechanisms implicated in the resistance of the etiologic agent. Even less is known about the role of each one of these factors in the follow-up of cryptococcosis. The research fields are numerous, and, given the stable morbidity and lethality rates associated with AIDS in Brazil, despite the existence of HAART and other advanced therapies, Brazilian researchers should contribute in clarifying predictor variables of clinical improvement of cryptococcosis.

REFERENCES


74. REZENDE, C. - Aspectos fenotípicos e moleculares de amostras de Cryptococcus neoformans da região de Araraquara e Ribeirão Preto, relacionados aos perfis de suscetibilidade. Ararquara, 2002. (Dissertação de Mestrado - Instituto de Química/UNESP).

75. REZENDE, D.G. - Isolamento de Cryptococcus neoformans de fezes de pombos e canários no Município de Alfenas, Alfenas, 2002. (Dissertação de Mestrado - Centro Universitário Federal de Alfenas).


Received: 18 June 2003
Accepted: 23 October 2003